Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-03-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
国元证券关于安科生物2021年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guoyuan Securities, the sponsor institution, regarding the 2021 annual special audit opinion on the deposit and use of raised funds by Anhui Anke Bioengineering (Group) Co., Ltd. It includes specifics on the amount of funds raised, their usage, management, and compliance with regulatory requirements. It also contains an auditor's verification opinion and a sponsor's verification opinion on the use of the raised funds. The document is focused on the annual review of the raised funds usage and management, which is a specialized audit report rather than a full annual report or interim financial report. It is not a brief announcement or a certification letter but a substantive report on the raised funds usage. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2021
2022-03-30 Chinese
关于召开2021年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of Anhui Anke Biotechnology (Group) Co., Ltd. It includes information about the meeting date, location, voting procedures (including online voting), agenda items to be discussed and voted on, and instructions for shareholders to participate. The document does not contain financial statements or results but rather the announcement and procedural details for the AGM. It is not a report of financial results or management discussion but a formal notification to shareholders about the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 4941 characters, which is consistent with a detailed AGM notice rather than a full annual report or other filings.
2022-03-30 Chinese
关于非公开发行部分限售股份解除限售的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the lifting of restrictions on certain restricted shares previously issued in a non-public offering. It details the number of shares becoming freely tradable, the shareholders involved, the dates of restriction lifting, and compliance with regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes specifics about shareholding changes and confirms that the unlocking of shares complies with relevant laws and regulations. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about share capital changes related to restricted shares becoming unrestricted and tradable. This fits the category of Share Issue/Capital Change announcements, as it concerns changes in share capital structure and share tradability status.
2022-03-29 Chinese
国元证券关于安科生物非公开发行部分限售股份解除限售的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from Guoyuan Securities regarding the lifting of restrictions on certain non-publicly issued shares of Anhui Anke Biotechnology (Group) Co., Ltd. It details the background of the share issuance, the lock-up period, the shareholders' compliance with commitments, and the arrangements for the shares to become freely tradable. The document includes regulatory references, shareholding details, and confirms compliance with relevant securities laws and stock exchange rules. It is not a financial report, earnings release, or management discussion, but rather a regulatory compliance and share unlocking announcement. Given the nature of the document as a formal verification and announcement related to share restriction removal, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories. The document length is 2801 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2022-03-29 Chinese
关于公司注射用人生长激素新增生产线获批的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a new production line for a pharmaceutical product. It includes details about the approval from a regulatory body (National Medical Products Administration) and the impact on production capacity and company competitiveness. The document is short (535 characters) and does not contain financial statements or detailed financial data. It is an operational update related to production capacity rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2022-03-28 Chinese
关于获得阿莫西林颗粒《药品补充申请批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of an official approval notice from the National Medical Products Administration for a pharmaceutical product (Amoxicillin Granules). It details the approval, product information, and risk warnings. The document is short (1130 characters) and serves as a regulatory announcement about a product approval, not a financial report or detailed filing. It does not contain financial statements, management discussion, or shareholder voting results. It is not an annual or interim report, nor a call transcript or capital update. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2022-03-21 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.